Florida State University cornea repair drug developer Trefoil Therapeutics added funding from investors including subsidiaries of Aju Corporation and Access Biotechnology to bring its total to $33.2m.

Trefoil Therapeutics, a US-based regenerative medicine spinout of Florida State University focused on endothelial damage to the cornea, obtained $28m yesterday in an oversubscribed series A round.
Venture capital firm Bios Partners led the round, with participation from Aju IB Investment and Access Biotechnology, investment arms of industrial conglomerates Aju and Access Industries respectively.
The round also featured VC firms Hatteras Venture Partners, Correlation Ventures, ExSight Ventures and InFocus Capital Partners, along with other, unspecified existing investors.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?